389630-95-9

Basic information

• Product Name: 1,3-THIAZOLE-2-BORONIC ACID
• Synonyms: thiazol-2-yl-2-boronic acid;(1,3-thiazol-2-yl)boronic acid;2-Thiazolyl-boronic acid;THIAZOLE-2-BORONIC ACID;1,3-THIAZOLE-2-BORONIC ACID;THIAZOL-2-YLBORONIC ACID;Thiazole-2-boronic acid dimethyl ester lithium methoxide salt, 90%
• CAS NO: 389630-95-9
• Molecular Formula: C₃H₄BNO₂S
• Molecular Weight: 128.95
• Mol File: 389630-95-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 320.926 °C at 760 mmHg
• Flash Point: 147.891 °C
• Appearance: /
• Density: 1.437 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.565
• PKA: 7.68±0.53(Predicted)
• CAS DataBase Reference: 1,3-THIAZOLE-2-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-THIAZOLE-2-BORONIC ACID(389630-95-9)
• EPA Substance Registry System: 1,3-THIAZOLE-2-BORONIC ACID(389630-95-9)

Safety Data

• Hazardous Substances Data: 389630-95-9(Hazardous Substances Data)

Usage

Description

1,3-Thiazole-2-borononic acid is an organic compound that features a thiazole ring with a boronic acid group attached to the second position. It is known for its chemical reactivity and potential applications in various fields due to its unique structure and properties.

Uses

Used in Pharmaceutical Industry:
1,3-Thiazole-2-borononic acid is used as a reactant for the preparation of arylbenzoxazoles, which are potent and selective receptor-β ligands. These ligands have potential applications in the development of drugs targeting specific receptors, which can be beneficial for treating various medical conditions.
Used in Chemical Synthesis:
1,3-Thiazole-2-borononic acid can be utilized as an intermediate in the synthesis of various organic compounds, particularly those containing the thiazole ring. Its reactivity with other molecules allows for the creation of a wide range of chemical products, making it a valuable compound in the field of organic chemistry.
Used in Material Science:
Due to its unique structure, 1,3-thiazole-2-borononic acid may also find applications in the development of new materials with specific properties. For instance, it could be used in the creation of novel polymers, coatings, or other materials with enhanced characteristics, such as improved stability, reactivity, or biocompatibility.

InChI:InChI=1/C3H4BNO2S/c6-4(7)3-5-1-2-8-3/h1-2,6-7H

Upstream product

• 288-47-1 1,3-thiazole 
• 121-43-7 Trimethyl borate 

Downstream Products

• 3704-41-4 2-(4-nitrophenyl)thiazole 
• 198904-53-9 4-(thiazol-2-yl)-benzaldehyde 
• 1292267-47-0 C₂₀H₁₅N₇S 
• 1292267-41-4 C₂₃H₂₀N₈OS 
• 868262-39-9 {methyl-[2-(3-thiazol-2-ylbiphenyl-4-yloxy)ethyl]-amino}-acetic acid tert-butyl ester 

Relevant articles and documents

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (c) (d) —C(O)NH—CH(R14)—C(O)NHSO2R16 (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4-L6—C(W)—N(R5)—L5—, (e) —L4-L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7-L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, and —P(W)RR3RR3′; R4is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.